Eagle Pharmaceuticals, a New Jersey-based pharmaceutical company, said that its product Ryanodex (dantrolene sodium) for injectable suspension inhibited the growth of SARS-CoV-2, the virus causing the COVID-19 pandemic, in a controlled in vitro laboratory test. On Tuesday, April 14, Eagle submitted its Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase 2 clinical trial in partnership with Hackensack University Medical Center to evaluate the effi...